02:35 PM EDT, 04/24/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month target price by $12 to $177, valuing GL shares at 10.7x our 2027 operating EPS estimate of $16.55 (raised today by $0.35) and at 11.3x our 2026 EPS estimate of $15.65 (lifted by $0.65). Our target multiples compare to GL's five-year average forward multiple of 10.3x and a bifurcated peer average of 11x. Q1 operating EPS of $3.43 vs. $3.07 a year ago topped our $3.35 operating EPS estimate, on a 5.4% rise in revenues, in line with our forecast for a 3% to 8% rise. Premiums rose by 6% in Q1, reflecting a 3% rise in life premiums (in line with our 3% to 6% growth forecast) and a 13% rise in health premiums (above our 5% to 9% growth forecast). We expect a similar growth trajectory for premiums in 2026. We are also encouraged by Q1 new sales trends, including a 6% rise in life sales and a 58% surge in health sales. We think this positive sales momentum provides the shares, currently trading below peers at 9.8x our 2026 EPS estimate, with a catalyst.